Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.31 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | RNMT | O43148 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008212 | 0.90 | ADORA3 (0.34) | ABL1ADORA3NAE1UBA3 | |
| SCHEMBL23080248 | 0.88 | — | — | |
| SCHEMBL20008116 | 0.86 | NAE1 (0.32) | NAE1UBA3 | |
| SCHEMBL20007973 | 0.85 | RET (0.35) | ADORA3RETADORA2AADORA1 | |
| SCHEMBL23080278 | 0.84 | ABL1 (0.39) | ABL1ADORA3RET | |
| SCHEMBL23080208 | 0.83 | ADK (0.32) | — | |
| SCHEMBL23080263 | 0.81 | ATG7 (0.32) | NAE1UBA3 | |
| SCHEMBL20007970 | 0.79 | DNPH1 (0.38) | CCNB2CDK1CCNB1CCNB3NAE1 | |
| SCHEMBL20008037 | 0.77 | ATG7 (0.40) | CCNB2CDK1CCNB1CCNB3NAE1 | |
| SCHEMBL20008059 | 0.76 | RET (0.33) | CCNB2CDK1CCNB1CCNB3NAE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | ABL1 2724/4885ADORA3 1669/4885CCNB2 238/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | ABL1 2833/4885ADORA3 3584/4885CCNB2 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.